AU2014254091B2 - Markers of tumor cell response to anti-cancer therapy - Google Patents

Markers of tumor cell response to anti-cancer therapy Download PDF

Info

Publication number
AU2014254091B2
AU2014254091B2 AU2014254091A AU2014254091A AU2014254091B2 AU 2014254091 B2 AU2014254091 B2 AU 2014254091B2 AU 2014254091 A AU2014254091 A AU 2014254091A AU 2014254091 A AU2014254091 A AU 2014254091A AU 2014254091 B2 AU2014254091 B2 AU 2014254091B2
Authority
AU
Australia
Prior art keywords
mir
tumor
drug
patient
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2014254091A
Other languages
English (en)
Other versions
AU2014254091A1 (en
Inventor
Gustavo Droguett
David Frendewey
Matthew Koss
Gavin Thurston
George D. Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2014254091A1 publication Critical patent/AU2014254091A1/en
Application granted granted Critical
Publication of AU2014254091B2 publication Critical patent/AU2014254091B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014254091A 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy Expired - Fee Related AU2014254091B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361812033P 2013-04-15 2013-04-15
US61/812,033 2013-04-15
PCT/US2014/034217 WO2014172376A2 (en) 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy

Publications (2)

Publication Number Publication Date
AU2014254091A1 AU2014254091A1 (en) 2015-11-12
AU2014254091B2 true AU2014254091B2 (en) 2019-03-21

Family

ID=51686961

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014254091A Expired - Fee Related AU2014254091B2 (en) 2013-04-15 2014-04-15 Markers of tumor cell response to anti-cancer therapy

Country Status (14)

Country Link
US (2) US10023916B2 (enExample)
EP (1) EP2986739B1 (enExample)
JP (1) JP2016518124A (enExample)
KR (1) KR20150140728A (enExample)
CN (1) CN105308189B (enExample)
AU (1) AU2014254091B2 (enExample)
BR (1) BR112015026095A8 (enExample)
CA (1) CA2909642A1 (enExample)
MX (1) MX2015014486A (enExample)
MY (1) MY180365A (enExample)
RU (1) RU2664180C2 (enExample)
SG (2) SG10201708464TA (enExample)
WO (1) WO2014172376A2 (enExample)
ZA (1) ZA201507309B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9510569B2 (en) 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
KR20150140728A (ko) 2013-04-15 2015-12-16 리제너론 파마슈티칼스 인코포레이티드 항암요법에 대한 종양 세포 반응의 표지들
CN104388561A (zh) * 2014-11-14 2015-03-04 浙江理工大学 肝癌生物标记物及其用途
CN106636311B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 大肠癌相关microRNA检测试剂盒
CN106636315B (zh) * 2015-10-30 2020-06-02 益善生物技术股份有限公司 淋巴瘤相关microRNA检测试剂盒
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
CN105950768A (zh) * 2016-07-01 2016-09-21 江苏医诺万细胞诊疗有限公司 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法
CN106350582B (zh) * 2016-08-25 2020-02-14 朱伟 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
CN107913284B (zh) * 2016-10-09 2022-09-16 上海市东方医院 miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用
CN106778073B (zh) * 2017-01-19 2019-09-06 北京吉因加科技有限公司 一种评估肿瘤负荷变化的方法和系统
CN106834470A (zh) * 2017-02-17 2017-06-13 张灏 miRNA在制备癌症诊断试剂盒中的用途
CN106676196B (zh) * 2017-03-10 2019-05-07 上海核盾生物科技有限公司 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒
CN107326092B (zh) * 2017-08-25 2021-07-20 深圳市恩普电子技术有限公司 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用
CN108220381A (zh) * 2017-12-07 2018-06-29 国家卫生计生委科学技术研究所 试剂在制备药物中的用途以及筛选药物的方法
CN108531586B (zh) * 2018-03-19 2022-03-29 朱伟 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用
CN109097473A (zh) * 2018-08-24 2018-12-28 南京求臻基因科技有限公司 一种非小细胞肺癌辅助诊断试剂盒
KR102256747B1 (ko) * 2018-10-30 2021-05-25 가톨릭대학교 산학협력단 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도
TWI894130B (zh) 2018-12-03 2025-08-21 美商艾澤西公司 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法
CN109593852B (zh) * 2018-12-24 2022-03-08 朱伟 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用
WO2020232474A1 (en) * 2019-05-15 2020-11-19 The University Of Chicago Lactate response system and methods
CN110484620B (zh) * 2019-08-09 2023-09-19 深圳市第二人民医院 生物标志物及其在制备诊断ptmc的产品中的应用
WO2021108043A1 (en) 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
KR102293777B1 (ko) * 2019-12-31 2021-08-25 연세대학교 산학협력단 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법
US20230037966A1 (en) * 2020-01-07 2023-02-09 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
CN113930505B (zh) * 2020-03-30 2022-04-19 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒及装置
CN111808950B (zh) * 2020-06-02 2023-11-14 中南大学湘雅医院 一种甲状腺乳头状癌miRNA标志物及其应用
JP2023530978A (ja) * 2020-06-19 2023-07-20 アジェンシス，インコーポレイテッド 抗体薬物複合体（ａｄｃ）によるがんの治療のための方法に使用するためのマーカー
CN111676291B (zh) * 2020-07-14 2021-04-13 徐州医科大学 一种用于肺癌患病风险评估的miRNA标志物
CN113025713B (zh) * 2021-02-23 2022-11-22 浙江东睿生物科技有限公司 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
CN114150063B (zh) * 2021-12-09 2024-12-17 觅瑞（杭州）生物科技有限公司 膀胱癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
EP4547872A1 (en) * 2022-07-01 2025-05-07 City of Hope Biomarkers in colorectal cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035709A2 (en) * 2005-09-20 2007-03-29 Scinopharm Singapore Pte, Ltd. Novel crystal forms of irinotecan hydrochloride

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059179A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceutical Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
AU2005265067B2 (en) * 2004-06-18 2010-12-16 Genentech, Inc. Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
ES2447850T3 (es) * 2006-07-13 2014-03-13 The Ohio State University Research Foundation Métodos y composiciones basados en micro-ARN para el pronóstico y tratamiento de enfermedades relacionadas con el colon
BRPI0716944A2 (pt) * 2006-09-19 2013-09-17 Novartis Ag biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf
WO2008143795A1 (en) 2007-05-11 2008-11-27 Champions Biotechnology, Inc. Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing
AU2009219197B2 (en) * 2008-02-28 2014-04-10 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dep. Of Health And Human Services MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
US20110107440A1 (en) 2008-06-04 2011-05-05 Andor Pivarcsi Skin cancer associated micrornas
US8399222B2 (en) * 2008-11-25 2013-03-19 Gen-Probe Incorporated Compositions and methods for detecting small RNAs, and uses thereof
JP6143041B2 (ja) * 2009-09-30 2017-06-07 公益財団法人ヒューマンサイエンス振興財団 大腸がん検査キット
WO2011156777A1 (en) * 2010-06-10 2011-12-15 Fred Hutchinson Cancer Research Center Use of blood mir-210 for cancer prognosis
CA2830301A1 (en) 2011-03-18 2012-09-27 Baylor Research Institute Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
US20140228233A1 (en) * 2011-06-07 2014-08-14 Traci Pawlowski Circulating biomarkers for cancer
WO2012174293A2 (en) * 2011-06-14 2012-12-20 Nestec Sa Methods for identifying inflammatory bowel disease patients with dysplasia or cancer
WO2014078850A1 (en) * 2012-11-19 2014-05-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery
KR20150140728A (ko) 2013-04-15 2015-12-16 리제너론 파마슈티칼스 인코포레이티드 항암요법에 대한 종양 세포 반응의 표지들

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035709A2 (en) * 2005-09-20 2007-03-29 Scinopharm Singapore Pte, Ltd. Novel crystal forms of irinotecan hydrochloride

Also Published As

Publication number Publication date
US10023916B2 (en) 2018-07-17
US20180291468A1 (en) 2018-10-11
US20140308370A1 (en) 2014-10-16
RU2015148638A (ru) 2017-05-22
EP2986739A2 (en) 2016-02-24
BR112015026095A2 (pt) 2017-07-25
WO2014172376A3 (en) 2015-10-29
ZA201507309B (en) 2017-08-30
MX2015014486A (es) 2016-07-21
CN105308189B (zh) 2018-09-04
CA2909642A1 (en) 2014-10-23
EP2986739A4 (en) 2017-03-01
CN105308189A (zh) 2016-02-03
MY180365A (en) 2020-11-28
KR20150140728A (ko) 2015-12-16
SG11201508058TA (en) 2015-10-29
AU2014254091A1 (en) 2015-11-12
JP2016518124A (ja) 2016-06-23
BR112015026095A8 (pt) 2020-01-21
HK1214630A1 (en) 2016-07-29
WO2014172376A2 (en) 2014-10-23
EP2986739B1 (en) 2018-04-04
SG10201708464TA (en) 2017-11-29
RU2664180C2 (ru) 2018-08-15

Similar Documents

Publication Publication Date Title
AU2014254091B2 (en) Markers of tumor cell response to anti-cancer therapy
Kong et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis
US9920375B2 (en) Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
JP5976726B2 (ja) 前立腺関連障害の予後診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
EP3520775A1 (en) Methods for treating cancer and predicting drug responsiveness in cancer patients
EP3342879A1 (en) Methods for predicting drug responsiveness in cancer patients
CN103492566B (zh) 乳癌患者对曲妥珠单抗的治疗敏感性预测用组合物和方法
US10900089B2 (en) Methods for predicting drug responsiveness in cancer patients
CN104093859A (zh) 多基因生物标志物的鉴定
CA2608359A1 (en) Gene expression signatures for oncogenic pathway deregulation
EP3122905B1 (en) Circulating micrornas as biomarkers for endometriosis
CA3032827A1 (en) Methods for diagnosing and treating esophageal cancer
WO2013082105A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
HK1214630B (en) Markers of tumor cell response to anti-cancer therapy
HK40049419A (en) Circulating micrornas as biomarkers for endometriosis
HK40006425A (en) Methods for treating cancer and predicting drug responsiveness in cancer patients
HK1262015A1 (en) Methods for predicting drug responsiveness in cancer patients
Kheirelseid Clinical applications of molecular profiling in colorectal cancer

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee